/ /

Advances in moderate-to-severe Atopic Dermatitis

Novel immunomodulators expected to usher in new therapeutic eraA number of systemic and topical treatments for atopic dermatitis are being developed that feature novel mechanisms of action targeting the inflammatory axes involved in the disease.
Phase 3 results demonstrate dupilumab efficacyNew data suggests positive safety and efficacy profile. Further studies need to assess long-term use.
Study offers new insight into pediatric eczema
Study offers new insight into pediatric eczemaResearchers have identified the skin phenotype of pediatric atopic dermatitis (AD) — a finding that challenges the notion of filaggrin's central role in the disease.
Crowdsourcing pinpoints unmet needs in eczema researchA new study using crowdsourcing harnesses the power of social media chatter to better understand unmet needs in eczema research.
Appreciating the role of microbial communities on the skinMicrobial colonization in the development of inflammatory conditions and immune-mediated conditions is a hot research topic, and new dermatologic therapies can potentially result from greater understanding of the role of microbial communities on the skin and in the gut.
Survey puts spotlight on a big problem for children with eczema: BullyingMany children with eczema suffer from bullying because of the skin condition. A new survey reflects what children and caregivers are experiencing, beyond the itch.
MMF relatively safe for off-label use in children, adults with severe ADFor patients with severe AD, treatment with the systemic immunomodulator methotrexate mycophenolate mofetil is a viable option, according to a recent review of the drug.
Pattern distinguishes atopic, contact dermatitisPart of the management of contact dermatitis is identifying the offending agent through patch testing and eliminating contact with the offending agent.
Investigative eczema drug shows positive phase 2 resultsUK-based Ziarco Pharma Ltd. recently announced positive phase 2a results for ZPL-389, a once daily oral histamine H4 receptor antagonist, for the treatment of moderate to severe atopic dermatitis.
Dupilumab demonstrates promising resultsThe systemic therapy dupilumab met primary endpoints in two phase 3 studies on adults with in inadequately controlled moderate-to-severe atopic dermatitis.